Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab + Erlotinib in Relapsed NSCLC
NCT00855894Phase 2Completed
- Sponsor
- Genentech
- Start
- Mar 2009
- Primary completion
- Mar 2012
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of pertuzumab in non-small cell lung cancer (NSCLC), sponsored by Genentech. Primary endpoint: Percentage of Patients With a 2-deoxy-2-[18F]Fluoro-D-glucose-positron Emission Tomography (FDG-PET) Response at Day 56. Started Mar 2009; status: completed.
02
Drugs
pertuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00855894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00855894.